SAN DIEGO, Oct. 11, 2018 — Medical Marijuana, Inc. (OTC:MJNA), the first-ever publicly traded cannabis company in the United States, announced today that the company’s Chief Executive Officer Dr. Stuart Titus will speak about Humulus-derived cannabidiol (CBD) at the CBD Outlook Conference on Oct. 16 in Denver.
Hosted at the University of Denver, CBD Outlook will focus on the science and business of cannabinoid development, with topics including key research initiatives, the 2018 Farm Bill and new innovations within the cannabis industry. The conference will feature 25 experts, 9 panels and numerous networking events for leaders within the industry.
Dr. Titus’ presentation entitled “Humulene (Hops) and CBD Design” will take place at 2 p.m. in Lecture Hall 229. He will discuss the research and development that the company’s partner Peak Health conducted to create the first-ever, and only, Kriya brand Humulus-derived CBD extract, which is now sold by Medical Marijuana, Inc. as Real Scientific Humulus Oil (RSHO-K). Dr. Titus will also be available to network with other industry leaders, offer media interviews and help educate those in attendance on the benefits of CBD.
“I am thrilled to speak at this year’s CBD Outlook on the exciting topic of Humulus-derived CBD,” Titus said. “There is immense value in having non-cannabis derived CBD, as it presents an alternative for customers who want to experience the benefits of CBD but cannot use cannabis. This event will offer a great opportunity to clarify any questions people may have on this revolutionary product.”
About Medical Marijuana, Inc.
We are a company of firsts®. Our mission is to be the premier cannabis and hemp industry innovators, leveraging our team of professionals to source, evaluate and purchase value-added companies and products, while allowing them to keep their integrity and entrepreneurial spirit. We strive to create awareness within our industry, develop environmentally-friendly, economically sustainable businesses, while increasing shareholder value. For details on Medical Marijuana, Inc.’s portfolio and investment companies, visit www.medicalmarijuanainc.com.
To see Medical Marijuana, Inc.’s corporate video, click here.
Shareholders and consumers are also encouraged to buy CBD oil and other products at Medical Marijuana, Inc.’s shop.
This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks, uncertainties and other factors, which may cause the actual results, performance or achievements of Medical Marijuana, Inc. to be materially different from the statements made herein.
FOOD AND DRUG ADMINISTRATION (FDA) DISCLOSURE
These statements have not been evaluated by the FDA and are not intended to diagnose, treat or cure any disease.
Medical Marijuana, Inc. does not sell or distribute any products that are in violation of the United States Controlled Substances Act (US.CSA). These companies do grow, sell, and distribute hemp-based products and are involved with the federally legal distribution of medical marijuana-based products within certain international markets. Cannabidiol is a natural constituent of hemp oil.
Public Relations Contact:
Chief Executive Officer